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Abstract 
 
 
 
 
Introduction: The INTEGRATE-HTA project provided methodology to evaluate complex technologies. 
This paper provides guidance on how to retrieve and critically appraise available evidence on 
moderators and predictors of treatment effects and on patient preferences for treatment outcomes 
as a source of complexity.  
Methods: search filters for PubMed were developed by hand-searching a large volume of articles 
reporting on relevant aspects. Search terms were retrieved from selected papers and algorithmically 
combined to find the optimal combination of search terms. For the development of the appraisal 
checklists literature was searched in PubMed and Google Scholar together with citation chasing. For 
the Checklist for the Appraisal of Moderators and Predictors (CHAMP) a Delphi procedure was used 
to value a set of eligible appraisal criteria retrieved from the literature.  
Results: search filters were developed optimized for different accuracy measures. The final version of 
CHAMP consists of a 17 questions covering the design, analysis, results and transferability of results 
of moderator and predictor analysis. The final checklist for appraisal of literature on patient 
preferences for treatment outcomes consist of six questions meant to help the user to indentify 
relevant quality issues together with a guidance towards existing tools concerning the appraisal of 
specific preference elicitation methods. 
Conclusion: Incorporating knowledge on subgroups for whom a specific treatment will produce more 
benefit holds the promise of better targeting and, ultimately, enhancing overall effectiveness and 
efficiency of healthcare technology. Finally, incorporating information on preferences for treatment 
outcomes will foster HTA that addresses outcomes that are important to patients. 
 
Keywords: INTEGRATE-HTA, moderators, predictors, patient preferences, complex interventions, 
health technology assessment 
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Introduction 
Traditionally, Health Technology Assessment (HTA) focuses on effectiveness and cost-effectiveness 
while other domains as part of the original definition of HTA such as ethical, legal and social aspects 
have been neglected. Within the INTEGRATE-HTA project we advocate for integration of social 
cultural, ethical, legal, organizational issues with effectiveness and cost-effectiveness (1). Social 
cultural, ethical and legal aspects present within the context may interact with the intervention 
which might make an intervention  complex. If an HTA process fails to take into account the 
complexity of an intervention then it could result in misleading conclusions (1). 
Another source of complexity, studied in work package 4 of the INTEGRATE-HTA project, is 
heterogeneity in patient characteristics and preferences for treatment outcomes. Depending on their 
characteristics patients may respond differently to a specific treatment, both in terms of beneficial or 
adverse effects. Moreover, patients may differ in how they value particular treatment outcomes. For 
instance, in the context of treatment of patients with epilepsy, a specific drug may be known to lead, 
on average, to slightly superior control of seizures, improved mood, but also weight gain. Even 
though this superiority may be true on average, seizure control will be better achieved in some 
patients using other drugs. Also, weight gain, if it occurs, may be less of a problem to some patients 
when compared with others.  
This example illustrates the need for information about moderators and predictors of 
treatment effects as well as patient preferences for specific treatment outcomes. First, information 
about moderators or predictors can be used to guide the search for subgroup analyses. Furthermore, 
the effectiveness of an intervention under assessment could be enhanced by targeting the treatment 
to a group that is most likely to benefit and thus guide implementation of a new intervention. 
Information about patient preferences for treatment outcome may be used to guide the 
effectiveness evaluation so as to ensure that this preferred outcome becomes one of the most 
important outcomes in the evaluation. Furthermore, in the decision making process following an 
HTA, one could give greater weight to results on outcomes that matter to patients most.  
The objective of work package 4 of the INTEGRATE-HTA project was to develop tools to 
efficiently retrieve and critical appraise available evidence on (i) moderators and predictors of 
treatment effects as well as on (ii) patient preferences for treatment outcomes, using search filters 
and critical appraisal tools. This paper takes the perspective of HTA researchers who wish to use the 
best available evidence to develop recommendations about how, and for whom, healthcare 
technologies may be optimally targeted. This paper summarizes previously published guidance (2) 
and offers insight into how the tools can be used by HTA researchers or agencies.  
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Moderators and predictors of treatment effects 
Moderators are variables which influence the strength of a relation between two other variables, for 
instance those for a treatment and an effect (3-5). Age and gender are common moderators. The 
term  ?ŵŽĚĞƌĂƚŽƌ ?is similar to the epidemiological term  ?ĞĨĨĞĐƚ ŵŽĚŝĨŝĞƌ ? ĂŶĚthe statistical term 
 ?ŝŶƚĞƌĂĐƚŝŽŶ ? (6). In practice it could mean that a treatment could work for men but not equally well 
for women. Predictors are characteristics or variables that influence the outcome independent of the 
treatment. The effect would be the same if a different treatment was applied. For instance gender is 
a predictor for mortality but when treatment had equal effects in men and women, gender is a 
predictor and not a moderator. Moderators can be investigated using subgroup analyses or 
regression analysis using interaction terms. Predictors can be investigated by looking at measures of 
association as in regression analyses (7-9). 
 
Search filters 
Efficiently identifying and using information from the literature concerning moderators or predictors 
of treatment effect requires an appropriate search strategy. As an alternative for hand searching the 
literature, a well defined search strategy is more efficient in retrieving relevant articles and allows for 
replication of results ďǇŝƚ ?ƐƚƌĂŶƐƉĂƌĞŶĐǇ. PubMed Clinical Query (PCQ) filters have been developed 
to find literature on prognosis, treatment or clinical prediction guides. These filters produce results 
containing articles concerning diagnosis or disease stage, study design/methodology, clinical 
prediction (i.e. prognosis, independent of treatment), outcome measures (including patient reported 
outcomes and quality of life) or treatment effects in general. A search filter specifically aimed at 
retrieving studies reporting on moderators of treatment outcome (i.e. variables that influence how 
well or likely a patient responds to a treatment) could have added value to existing filters.  
Such a search filter was created by first collecting relevant articles on moderators and 
predictors of treatment effects. All articles published in the year 2011 in specific journals in the field 
of rheumatoid arthritis and general medicine were searched by hand and any of these reporting 
moderators or predictors of treatment effects were selected. Subsequently, search terms identified 
from these papers were algorithmically combined to derive the optimal combination of search terms 
for finding articles on moderators and predictors of treatment effects. The applied methods followed 
accepted good practice in search filter creation (10, 11). More details on the development on the 
search filters can be found in the Guidance for the assessment of treatment moderators and 
ƉĂƚŝĞŶƚƐ ? preferences (2). 
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This methodology resulted in four sets of search filters, which were tested on the same hand 
searched set of papers. The results are listed in table 1. Each set contains the top three search filters 
optimized for the respective performance measure. If the purpose of an HTA is to be exhaustive, the 
filter optimized for sensitivity will be most appropriate. However it will probably return a relatively 
large proportion of papers of low relevance. Search filters with high accuracy, specificity or low 
number of papers needed to screen (Number Needed to Read (NNR) (12) will return fewer irrelevant 
papers at the expense of missing potentially important information. Clearly, the choice of which 
strategy to use depends on the goal of the systematic review, the numbers of usable retrieved 
papers and the amount of time that the user is willing and able to invest. The chosen search filter 
needs to be combined with a disease specific search filter relevant to the field of interest. We do not 
recommend to combine the search filters with any limits on publication type, since moderators and 
predictors are reported in epidemiological studies, randomised controlled trials (RCTs) as well as 
meta-analysis (7-9). 
 
Critical appraisal tool 
Once relevant literature has been selected, the next step is to assess it for quality. Two critical 
appraisal tools for prediction and moderation of treatment effect, based on Randomised Controlled 
Trials (RCTs), have previously been published (13, 14). However, relevant and valid moderator or 
predictor information is also found in studies other than RCTs. Also, such information may be derived 
from a body of evidence, as represented within a systematic review, rather than solely from single 
studies. Therefore, within work package 4 of the INTEGRATE-HTA project, we developed a more 
flexible critical appraisal tool suitable for all alternatives of moderator/ predictor (or subgroup) 
analyses. 
For the development of the tool, we conducted a preliminary literature review of aspects 
important for validity of moderators and predictors of treatment effect. This review was based on 
searches in PubMed and Google Scholar, citation chasing, author searches, related articles and 
consultation with experts. As the aim was not to itemise every single aspect of validity, but simply to 
identify a diverse range of indicative factors, we did not aim for comprehensive coverage of the 
literature. Forty-nine appraisal criteria were identified in the literature. Subsequently, a Delphi 
procedure with three rounds was used, following the Research and Development (RAND) 
Appropriateness Method guidelines (15), to augment and then value a set of appraisal criteria 
retrieved from the literature. Fourteen experts from (bio)statistics, epidemiology and other 
associated fields participated in the Delphi procedure.Based on these results, a final selection of 
criteria was included in a test version of the appraisal checklist. Following internal testing and 
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external feedback the test version was amended to create a final version. We would like to refer to 
ƚŚĞ 'ƵŝĚĂŶĐĞ ĨŽƌ ƚŚĞ ĂƐƐĞƐƐŵĞŶƚ ŽĨ ƚƌĞĂƚŵĞŶƚ ŵŽĚĞƌĂƚŽƌƐ ĂŶĚ ƉĂƚŝĞŶƚƐ ? preferences (2) for more 
details about the development of the tool and the results of the difference Delphi rounds and testing 
phases. Please note that work on the checklist was completed after the guidance was published. We 
are currently working on an update of the guidance. 
The final version of the CHecklist for the Appraisal of Moderators and Predictors (CHAMP) 
consists of a 17 questions (listed in table 3), each completed ĂƐ  ?ǇĞƐ ? ?  ?ŶŽ ? ?  ?ĚŽŶ ?ƚ ŬŶŽǁ ? Žƌ  ?ŶŽƚ
ĂƉƉůŝĐĂďůĞ ? ?Those 17 items cover the design (e.g. a priori plausibility), analysis (e.g. use of interaction 
tests) and results (e.g. complete reporting) of moderator and predictor analysis, together with the 
transferability of the results. Using the checklist should help to arrive at a transparent and uniform 
overall judgement of the quality of a moderator or predictor analysis. CHAMP can be used to 
determine whether evidence is sufficient to warrant subgroup analyses in meta-analyses; to 
systematically value and describe evidence in systematic reviews; to design prediction models, and to 
facilitate individualised healthcare. CHAMP is designed to be used in conjunction with a quality tool 
such as the Cochrane risk of bias tool (16), to judge the overall quality of the study. 
 
 
 
Patient preferences for treatment outcomes 
The value of a specific technology for a defined individual does not only depend on moderators and 
predictors but also on their personal preferences. The importance of incorporating patients' 
preferences in medical decision making is increasingly recognized. The importance of patient 
preferences for treatment outcomes can be illustrated by the example of an HTA of the paediatric 
cochlear implant. Whereas the literature mainly reported outcomes for hearing and speech, the deaf 
community was at least equally interested in social and emotional development outcomes (17). In a 
further example, patients with chronic kidney disease differed regarding the weight they assigned to 
various hemodialysis-related outcomes when compared to the views of nephrologists and HTA 
authors (18). Both examples illustrate that interventions may be considered superior in aspects 
deemed important to medical professionals or decision makers but not to patients. The value of 
interventions should, therefore, also be established from the viewpoint of the target population, i.e. 
the patients.  
WĂƚŝĞŶƚƐ ? ƉƌĞĨĞƌĞŶĐĞƐ ĂƌĞ ƵƐƵĂůůǇ ĚĞƐĐƌŝďĞĚ ĂƐ Ă ƉƌĞĨĞƌĞŶĐĞ for one treatment or another. 
These preferences are difficult to generalize as they are highly context-dependent (19). Therefore, it 
is more relevant to retrieve information on treatment outcomes which might explain such 
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preferences, e.g. risks on adverse events, or specific outcomes such as functional status. Searching 
for information on preferences for treatment outcomes in the medical literature, for instance using 
PubMed, can be time-consuming (20, 21) and may be problematic since patient preferences are 
elicited in many ways (21, 22). Heterogeneity in methods used and reporting styles makes it more 
difficult to retrieve relevant literature (23). Therefore, we developed a search filter, similar to 
PubDĞĚ ?ƐůŝŶŝĐĂůYƵĞƌŝĞƐ ?ǁŝƚŚŚŝŐŚƉĞƌĨŽƌŵĂŶĐĞin retrieving scientific papers that report empirical 
evidence on patients' preferences for treatment outcomes (24). 
Search filters 
Development of search filters for patient preferences followed a similar process to that for the filters 
for finding moderators and predictors: [1] a comprehensive set of search terms and combinations of 
terms was constructed and [2] the results of these combinations of terms were tested in a set of 
relevant papers. This methodology resulted in a set of search filters either optimized for sensitivity, 
specificity, accuracy or NNR as shown in Table 2 (24).  
Testing revealed that papers on patient preferences in general and for treatment outcomes, 
specifically, are a needle in the medical literature haystack. Only 22 of all 8238 hand-searched articles 
(0.27%) reported empirical evidence on patientƐ ? preferences for treatment outcomes. We identified 
three possible reasons for this finding: i) there is little research performed on this subject; ii) the 
research is inadequately reported and cannot be retrieved at a title or abstract level; or iii) the 
journals we had carefully preselected do not commonly publish papers on preferences. Based on this 
finding we recommend starting with the sensitivity-optimised filters. When the initial set of retrieved 
literature seems unmanageably large, then a specificity-optimised filter can be used. 
Inevitably, the performance of the search filters presented in this paper reflects the 
terminology used by researchers to publish ƚŚĞŝƌ ǁŽƌŬ ŽŶ ƉĂƚŝĞŶƚƐ ? ƉƌĞĨĞƌĞŶĐĞƐ ĨŽƌ ƚƌĞĂƚŵĞŶƚ
outcomes in 2011. Any changes in terminology over time affects the performance of search filters. 
For this reason, ongoing update of the performance of these search filters on a periodic basis is 
warranted. 
 
Critical appraisal checklist 
The aim of the appraisal checklist is to determine whether a study reporting on patient preferences 
for treatment outcomes has (i) been executed rigorously and (ii) whether the findings are relevant to 
the research questions of the HTA. Given the diversity of methods to elicit preferences, quantitative 
as well as qualitative, it did not seem feasible to develop one generic tool including items relevant to 
all study designs. Therefore, we mapped the methods currently being used to elicit patient 
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preferences for treatment outcomes and then searched for existing guidance or tools to appraise 
these methods. 
To explore methodologies most commonly used to elicit patient preferences for treatment 
outcome, we analysed the papers identified during development of the search strategy, as well as 
expert opinion, and conducted additional PubMed and Google Scholar searches. A separate search 
was performed, for each method found, to identify appraisal criteria specific to that method. These 
searches combined method-related search terms with appraisal related search terms, such as 
'appraisal' or 'quality'. The search identified various studies that detail quality criteria of potential 
value when appraising studies on patient preferences for treatment outcomes.  
Despite the large variety of methods available to elicit patient preferences (25), we identified 
considerable overlap in how data are collected or interpreted across methods. Grouping of appraisal 
criteria was performed primarily on a conceptual, not a methodological, basis. Following creation of a 
test version, the tool was tested in a case study and revised following user feedback. 
The final checklist consists of six questions (listed in table 4), each completed ĂƐ  ?ǇĞƐ ? ?  ?ŶŽ ? ?
 ?ĚŽŶ ?ƚ ŬŶŽǁ ? Žƌ  ?ŶŽƚ ĂƉƉůŝĐĂďůĞ ? ? The checklist, including an in-depth explanation of the rationale 
behind each question, is presented in the supplementary file. By answering the individual items, 
users should be able to identify relevant quality issues. The items in the checklist can be considered 
as a set of key quality indicators: the more these criteria are met, the greater the likelihood that a 
study was adequately conducted. For appraisal of specific aspects, or to determine the 
appropriateness of the method, will require in-depth knowledge of the specific methods used. 
 
Application of the tools within INTEGRATE-HTA 
In terms of the INTEGRATE-HTA process (26), information about moderators and predictors for 
treatment effects as well as the patient preferences for treatment outcome are best used as input 
for a logic model (27). A logic model can be used to conceptualize the complexity of a technology by 
making a graphical description of a system within which the technologies operate, its elements and 
any relationships within the system. On the one hand, information on preferences and potential 
moderators or predictors can be use to guide the effectiveness assessment. On the other hand, social 
cultural, ethical, or legal issues may determine or moderate either the preferences for treatment 
outcomes or treatment effects itself. This information may be looped back into the INTEGRATE-HTA 
process model (26) and into the logic model, making it a more comprehensive, iterative and 
integrated process.  
This process is illustrated by the HTA on reinforced models of palliative care which served as 
a case study in the INTEGRATE-HTA project (28). The developed search filters and appraisal tools 
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were tested within this case study. According to the evidence retrieved, many patients receiving 
palliative care expressed a strong preference to die at home, in their familiar surroundings, an 
outcome not to be neglected when comparing different modalities of palliative care. Furthermore, 
the logic model should incorporate factors that may affect the likelihood of patients dying in their 
own familiar surroundings, as for example the presence of an informal caregiver.  
In addition, we found papers reporting on factors that influence preferences for treatment 
outcomes. For example, in the North-American setting, blacks and Hispanics are more likely to want 
to spend their last days in a hospital, and more likely to want life-prolonging drugs, when compared 
with Caucasians (29). This would mean that a home-based palliative care intervention does not per se 
fit the needs of patients from this ethnic background and will probably not result in the best 
outcomes for this group. 
Incorporating such information within an HTA may lead to a more targeted indication for 
particular services, as opposed to a  ?one size fits all ? approach. However, numerous, diverse factors 
could influence clinical decision making, especially when a complex intervention is involved. Each 
additional factor incorporated within the decision making process adds to complexity and may incur 
additional costs. Especially when determining a genetic profile, specific biomarkers or laboratory 
tests will add to the overall costs of the technology. Prior to implementation decision-makers will 
need to consider whether the extra costs of a more individualized approach will outweigh the 
benefits. However, use of information on treatment moderating and patient preferences in clinical 
decision-making holds the potential to improve the quality of care, efficiency of care and saving costs 
(30, 31).  
The proposed approach of INTEGRATE-HTA and in particular the results of work package 4 
are in contrast with the traditional HTA were the cost-effectiveness analysis plays central role. If a 
cost-effectiveness analysis is done from a societal perspective, which is preferred by most guideline 
of CE analyses, health states are valued from the perspective of the general population. Indeed from 
a societal perspective, accounting for fairness, societal values are preferred but from an individual 
perspective of the patient all kind of other outcomes could be preferred. Including patient 
preferences in HTA can increase public acceptance of health policy, increase transparency and 
legitimacy by involving stakeholders, and is therefore essential to good HTA practice (32). Therefore, 
we highly recommend that information about treatment moderation and patient preferences is 
incorporated within an HTA in order to target populations that will benefit the most and to assess 
value of outcomes that are prioritized by patients. 
 
Conclusion 
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This INTEGRATE-HTA work package  4 resulted in different tools to retrieve and critically appraise 
literature on moderators and predictors of treatment effects or patient preferences for treatment 
outcomes. Using the tools enables HTA researchers to retrieve information on subgroups for whom a 
specific treatment will produce more benefit. Incorporating this knowledge in the HTA process holds 
the promise of better targeting and, ultimately, enhancing overall effectiveness and efficiency of 
healthcare technology. Finally, incorporating information on preferences for treatment outcomes will 
foster HTA that addresses outcomes that are important to patients. 
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Table 1: Search filters for articles on moderators and predictors of treatment effects.  
Search filter Se (%) [95% CI] Sp (%) [95% CI] Ac (%) NNR 
KƉƚŝŵĂůƐĞŶƐŝƚŝǀŝƚǇ ?     
("Epidemiologic Methods"[mesh] OR assign* OR 
control*[tiab] OR trial*[tiab]) AND therapy[sh] 
89.1 [87.8 - 90.4] 80.2 [78.6 - 81.9] 80.6 5.59 
("Epidemiologic Methods"[mesh] OR assign* OR 
control*[tiab]) AND (therapy[sh] OR primary*[tiab])  
91.1 [89.9 - 92.3] 79.3 [77.6  ? 81.0] 79.8 5.71 
("Epidemiologic Methods"[mesh] OR analys* OR 
predict* OR trial*[tiab]) AND therapy[sh] 
92.1 [90.9 - 93.2] 79.9 [78.3 - 81.6] 80.5 5.51 
      
KƉƚŝŵĂůƐƉĞĐŝĨŝĐŝƚǇ ?     
group*[tw] AND therapy* 58.4 [56.4 - 60.5] 94.9 [94.0 - 95.8] 93.2 2.81 
randomi* AND treat* 61.4 [59.3 - 63.4] 94.6 [93.7 - 95.6] 93.1 2.81 
group*[tw] AND treat*[tw] 65.3 [63.4 - 67.3] 94.6 [93.7 - 95.6] 93.3 2.70 
      
KƉƚŝŵĂůĂĐĐƵƌĂĐǇ ?     
group*[tw] AND therapy* 58.4 [56.4 - 60.5] 94.9 [94.0 - 95.8] 93.2 2.81 
(randomi* OR hazard*) AND treat* 66.3 [64.4 - 68.3] 94.3 [93.3 - 95.3] 93.0 2.78 
randomi* AND treat* 61.4 [59.3 - 63.4] 94.6 [93.7 - 95.6] 93.1 2.81 
      
KƉƚŝŵĂůEEZ ?     
(randomi* OR hazard*) AND treat* 66.3 [64.4 - 68.3] 94.3 [93.3 - 95.3] 93.0 2.78 
(randomi* OR multivariate) AND treat* 66.3 [64.4 - 68.3] 94.1 [93.1 - 95.1] 92.8 2.85 
randomi* AND (treat* OR death*) 64.4 [62.4 - 66.4] 94.4 [93.5 - 95.4] 93.1 2.78 
Caption: Combinations of search terms with the best sensitivity, best specificity, and lowest NNR for 
detecting articles reporting on moderators or predictors of treatment outcome. Se: Sensitivity, Sp: 
Specificity, Ac: Accuracy, NNR: Number Needed to Read, [tiab] = title/abstract, words and numbers 
included in the title, collection title, abstract, and other abstract of a citation, [ti] = title, words and 
numbers included in the title or collection title.  ?Keeping sensitivity >=25%, specificity >=75%, and 
accuracy >= 75%. Mesh: Medical Subject Headings. Sh: subject heading 
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Table 2. Search filters for articles on patient preferences for treatment outcomes.  
Search term Se (%) [95% CI] Sp (%) [95% CI] Ac (%) NNR 
Best sensitivity*     
Preferen* 75.0 [73.7 - 76.3] 97.2 [96.7 - 97.7] 97.1 13.9 
Relat*[tiab] 75.0 [73.7 - 76.3] 79.5 [78.2 - 80.7] 79.4 94.8 
 "Middle Aged"[Mesh] 66.7 [65.2 - 68.1] 77.6 [76.3 - 78.9] 77.5 116.7 
     
Best specificity*     
Logit 33.3 [31.9 - 34.8] 99.8 [99.7 - 100.0] 99.6 2.8 
"Choice Behavior" [Mesh] 33.3 [31.9 - 34.8] 99.3 [99.0 - 99.6] 99.1 8.3 
"Patient Preference" [Mesh] 50.0 [48.5 - 51.5] 99.3 [99.0 - 99.5] 99.1 6.0 
     
Best accuracy*     
Logit 33.3 [31.9 - 34.8] 99.8 [99.7 -100.0] 99.6 2.8 
"Patient Preference"[mesh] 50.0 [48.5 - 51.5] 99.3 [99.0 - 99.5] 99.1 6.0 
Choice Behavior[mh] 33.3 [31.9 - 34.8] 99.3 [99.0 - 99.6] 99.1 8.3 
     
Lowest NNR*     
Logit 33.3 [31.9 - 34.8] 99.8 [99.7 - 100.0] 99.6 2.8 
"Patient Preference"[mesh] 50.0 [48.5 - 51.5] 99.3 [99.0 - 99.5] 99.1 6.0 
"Choice Behavior" [mesh] 33.3 [31.9 - 34.8] 99.3 [99.0 - 99.6] 99.1 8.3 
Caption: Combination of terms with the best sensitivity, best specificity, and lowest NNR. Se: 
Sensitivity, Sp: Specificity, Ac: Accuracy, NNR: Number Needed to Read, [tiab] = title/abstract, words 
and numbers included in the title, collection title, abstract, and other abstract of a citation, [ti] = title, 
words and numbers included in the title or collection title. *Keeping sensitivity >=25%, specificity 
>=75%, and accuracy >= 75%. Mesh: Medical Subject Headings. Sh: subject heading 
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Table 3: Questions in CHAMP for assessing moderators and predictors of treatment effects. 
Design 
1. A priori plausibility: was there sufficient empirical or theoretical support for the moderator or 
predictor that was examined?   
2. Was the moderator or predictor specified a priori?   
3. Was the moderator or predictor variable measured before the allocation or start of the 
intervention?   
4. Was measurement of the moderator or predictor reliable and valid in the target population? 
 
Analysis 
5. In case of a moderator, was an interaction test used?   
6. Was a limited number of moderators and predictors tested?   
7. Was sample size adequate for the moderator or predictor analysis?   
 
Results 
8. Were results presented for all candidate moderators or predictors that were examined? 
9. Did statistical tests or confidence intervals indicate that observed moderator or predictor 
effects were unlikely to be merely due to chance variation? 
10. Was the moderator or predictor effect consistent with related moderators or predictors, or 
across related outcomes measured within the study? 
 
Transferability 
11. Were the setting and study population comparable to the setting and population in which 
the information would be used?   
12. Is the moderator or predictor effect clinically important? 
 
Body of evidence 
13. Was the moderator or predictor effect consistent with related moderators or predictors, or 
across related outcomes measured between the studies?   
14. Were the setting and study population comparable to the setting and population in which 
the information would be used?   
15. Is the moderator or predictor effect clinically important?   
16. Was the moderator or predictor effect reasonably homogenous across studies?   
16 
 
17. Was the moderator or predictor measured similarly across the included studies, or was an 
adequate conversion performed? 
Note that questions 10-12 are listed twice, as they are applicable both to individual studies and sets 
of studies covering the same moderator or predictor (body of evidence). 
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Table 4: Questions in the appraisal tool for papers on patient preferences for treatment outcomes 
Appraisal items for patient preferences for treatment outcomes 
1. Does the study address relevant patient preferences for treatment outcome? 
2. Is the description of population, methods, and analysis clear and complete? 
3. Are the data collection methods appropriate and appropriately used? 
a. Is the format of included questions appropriate? 
b. Is the chosen mode of application for included questions appropriate? 
4. Are any theories, assumptions or models on which the research is based 
adequately described? 
5. Were the methods properly executed and the results reliable and valid? 
6. Are the results transferable to the target population? 
 
